Food and Drug Administration (FDA)
NEWS
Shares of Rigel Pharmaceuticals shot up about 40 percent during Thursday trading due primarily to an error on the company’s website that claimed its drug candidate Tavalisse had gained approval from the U.S. Food and Drug Administration (FDA).
One month after three patients who developed adverse reactions following injections of an unauthorized herpes vaccine filed a lawsuit against Rational Vaccines, the U.S. Food and Drug Administration has launched a criminal investigation into the matter.
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Novartis has struck a deal to acquire AveXis for $8.7 billion. Novartis will pay $218 per share, which is a 72 percent premium over AveXis’s 30-day volume-weighted average stock price.
As legal battles over opioid drugs slowly move through the courts the U.S. Department of Justice is adding its weight to the matter. This week the DOJ asked the courts for permission to help settle disputes brought by state and local governments against opioid manufacturers and distributors.
Shares of Alkermes plc are down about 19 percent in premarket trading after the U.S. FDA rejected the company’s NDA for its major depressive disorder treatment ALKS-5461.
Sunovion Pharmaceuticals announced it submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for apomorphine sublingual film to treat OFF episodes in Parkinson’s disease (PD).
A Novartis leukemia drug continues to be the subject of a handful of lawsuits filed by plaintiffs due to concerns over atherosclerosis-related conditions.
The U.S. Food and Drug Administration (FDA) approved Mylan NV’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients.This marks the third HIV approval for the company.
JOBS
IN THE PRESS